Zacks Research Has Strong Estimate for TSE:BHC Q3 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Investment analysts at Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will post earnings of $1.44 per share for the quarter, up from their previous forecast of $1.41. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $1.34 EPS, Q3 2026 earnings at $1.80 EPS and FY2026 earnings at $6.85 EPS.

Bausch Health Companies (TSE:BHC) last released its quarterly earnings data on Thursday, August 1st. The company reported C$1.22 EPS for the quarter, meeting analysts’ consensus estimates of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The business had revenue of C$3.29 billion for the quarter, compared to the consensus estimate of C$3.20 billion.

A number of other research analysts also recently commented on the company. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Raymond James upgraded Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 10th.

Bausch Health Companies Stock Performance

Bausch Health Companies has a 1-year low of C$5.45 and a 1-year high of C$15.43. The stock has a market cap of C$4.13 billion, a P/E ratio of -6.39, a P/E/G ratio of 0.21 and a beta of 0.77. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of 7,583.76. The firm has a 50 day simple moving average of C$9.50 and a 200-day simple moving average of C$9.95.

Insider Buying and Selling at Bausch Health Companies

In other Bausch Health Companies news, Senior Officer Seana Lynne Carson sold 13,370 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total value of C$112,087.40. Company insiders own 11.28% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.